Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IVA 
Inventiva Sa (IVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IVA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.78
1 Year Target Price $12.78
| 6 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.25% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 883.03M USD | Price to earnings Ratio - | 1Y Target Price 12.78 |
Price to earnings Ratio - | 1Y Target Price 12.78 | ||
Volume (30-day avg) 7 | Beta 0.62 | 52 Weeks Range 1.53 - 6.50 | Updated Date 08/29/2025 |
52 Weeks Range 1.53 - 6.50 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -384.43% |
Management Effectiveness
Return on Assets (TTM) -63.6% | Return on Equity (TTM) -1642.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 700168732 | Price to Sales(TTM) 62.65 |
Enterprise Value 700168732 | Price to Sales(TTM) 62.65 | ||
Enterprise Value to Revenue 65.41 | Enterprise Value to EBITDA -1.34 | Shares Outstanding 139060000 | Shares Floating 50519309 |
Shares Outstanding 139060000 | Shares Floating 50519309 | ||
Percent Insiders - | Percent Institutions 5.16 |
Upturn AI SWOT
Inventiva Sa
Company Overview
History and Background
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs. Founded in 2012, the company has progressed several compounds through preclinical and clinical development.
Core Business Areas
- NASH Drug Development: Inventiva focuses on developing Lanifibranor for the treatment of NASH. This segment involves clinical trials, regulatory submissions, and potential commercialization.
- Other Metabolic Diseases: Inventiva also explores therapies for other metabolic diseases, using its expertise in PPAR (peroxisome proliferator-activated receptor) modulation.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. Its organizational structure includes departments focused on research, clinical development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Lanifibranor: Lanifibranor is Inventiva's lead product candidate for the treatment of NASH. It is a pan-PPAR agonist. Market share is currently 0% as it's not approved. Competitors include Madrigal Pharmaceuticals (Resmetirom), Viking Therapeutics (VK2809), and Akero Therapeutics (Efruxifermin).
Market Dynamics
Industry Overview
The NASH market is a large and growing market with a high unmet need. Several companies are racing to develop effective therapies. The market is estimated to reach billions of dollars in the coming years.
Positioning
Inventiva is positioning itself as a leader in NASH treatment with Lanifibranor. Its competitive advantage lies in the pan-PPAR mechanism and potential efficacy.
Total Addressable Market (TAM)
The NASH market is projected to exceed $40 billion by 2030. Inventiva is aiming to capture a significant share of this market with Lanifibranor.
Upturn SWOT Analysis
Strengths
- Promising lead product candidate (Lanifibranor)
- Experienced management team
- Focus on a high unmet need market (NASH)
- Pan-PPAR agonist mechanism of action
Weaknesses
- Reliance on a single lead product candidate
- Limited commercial infrastructure
- High cash burn rate
- Regulatory approval risk
Opportunities
- Potential approval and commercialization of Lanifibranor
- Expansion into other metabolic diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
Threats
- Competition from other NASH therapies
- Regulatory hurdles
- Clinical trial failures
- Financial constraints
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- AKRO
Competitive Landscape
Inventiva faces significant competition in the NASH market. Its success depends on demonstrating superior efficacy and safety compared to existing and emerging therapies. Madrigal is furthest along with resmetirom, which is already approved.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable at this time due to limitations.
Future Projections: Future projections are highly dependent on the success of Lanifibranor in clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing Lanifibranor through Phase 3 clinical trials and seeking partnerships for commercialization.
Summary
Inventiva is a clinical-stage biopharmaceutical company focused on NASH, primarily through its lead drug candidate, Lanifibranor. Its success hinges on positive clinical trial outcomes and regulatory approval for Lanifibranor. Competition in the NASH market is fierce, requiring Inventiva to differentiate itself through superior efficacy or safety. The company's limited commercial infrastructure necessitates strategic partnerships for successful market penetration.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. The AI-based rating is based on a limited set of information and should be interpreted with caution. Financial metrics are unavailable at this time due to limitations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inventiva Sa
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-07-10 | Co-Founder, CEO & Director Mr. Frederic Cren | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://inventivapharma.com |
Full time employees 114 | Website https://inventivapharma.com | ||
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.